Piper Jaffray Companies began coverage on shares of Uniqure (NASDAQ:QURE) in a research note issued to investors on Friday, Benzinga’s Daily Ratings Newsletter reports. The firm issued an overweight rating and a $80.00 target price on the biotechnology company’s stock.

Several other research firms also recently weighed in on QURE. BidaskClub upgraded Uniqure from a buy rating to a strong-buy rating in a research report on Wednesday, March 13th. Wells Fargo & Co increased their target price on Uniqure from $65.00 to $90.00 and gave the stock an outperform rating in a research report on Friday, March 15th. Cantor Fitzgerald restated a buy rating and set a $81.00 price target on shares of Uniqure in a research note on Thursday, March 7th. Zacks Investment Research lowered Uniqure from a strong-buy rating to a hold rating in a research note on Wednesday, March 6th. Finally, Chardan Capital upped their price target on Uniqure from $70.00 to $100.00 and gave the stock a buy rating in a research note on Monday, March 4th. One investment analyst has rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company’s stock. The company has an average rating of Buy and a consensus price target of $74.73.

NASDAQ QURE opened at $57.95 on Friday. Uniqure has a twelve month low of $21.98 and a twelve month high of $69.60. The stock has a market cap of $2.19 billion, a P/E ratio of -24.76 and a beta of 1.08. The company has a current ratio of 11.85, a quick ratio of 11.85 and a debt-to-equity ratio of 0.20.

Uniqure (NASDAQ:QURE) last released its earnings results on Thursday, February 28th. The biotechnology company reported ($0.59) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.67) by $0.08. Uniqure had a negative return on equity of 47.73% and a negative net margin of 738.25%. On average, equities analysts anticipate that Uniqure will post -3.01 EPS for the current year.

In other news, Director David Schaffer sold 7,500 shares of the stock in a transaction dated Thursday, January 17th. The stock was sold at an average price of $30.71, for a total value of $230,325.00. Following the completion of the sale, the director now owns 43,701 shares in the company, valued at $1,342,057.71. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Alexander Edward Kuta III sold 1,052 shares of the stock in a transaction dated Monday, January 28th. The shares were sold at an average price of $31.29, for a total value of $32,917.08. Following the completion of the sale, the senior vice president now owns 26,578 shares of the company’s stock, valued at approximately $831,625.62. The disclosure for this sale can be found here. Insiders have sold 113,651 shares of company stock valued at $5,963,013 over the last 90 days. 1.56% of the stock is currently owned by insiders.

Hedge funds have recently bought and sold shares of the company. Legal & General Group Plc grew its stake in shares of Uniqure by 264.2% in the fourth quarter. Legal & General Group Plc now owns 965 shares of the biotechnology company’s stock valued at $28,000 after buying an additional 700 shares in the last quarter. Exane Derivatives acquired a new stake in shares of Uniqure in the fourth quarter valued at about $41,000. Advisor Group Inc. grew its stake in shares of Uniqure by 5.3% in the fourth quarter. Advisor Group Inc. now owns 9,966 shares of the biotechnology company’s stock valued at $288,000 after buying an additional 502 shares in the last quarter. HRT Financial LLC acquired a new stake in shares of Uniqure in the fourth quarter valued at about $289,000. Finally, Financial Gravity Companies Inc. acquired a new stake in shares of Uniqure in the fourth quarter valued at about $310,000. Institutional investors and hedge funds own 60.52% of the company’s stock.

Uniqure Company Profile

uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. It engages in developing AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia B; AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-130, a gene therapy for the treatment of Huntington's disease; and AMT-126, for the treatment of heart failure.

Further Reading: Day Trading

Analyst Recommendations for Uniqure (NASDAQ:QURE)

Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.